Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

December 7th 2025

Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

December 7th 2025

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

December 7th 2025

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

KRd Demonstrates Superior PFS vs VRd in Newly Diagnosed Myeloma

December 6th 2025

KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

December 6th 2025

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

December 6th 2025

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

Experts Prepare for Several Key MCL Presentations at ASH 2025

December 5th 2025

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC

December 5th 2025

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

December 5th 2025

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence

December 5th 2025

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

FDA Approves Liso-Cel for Relapsed/Refractory Marginal Zone Lymphoma

December 4th 2025

The FDA approved liso-cel for relapsed/refractory MZL after 2 prior lines of therapy.

Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025

December 4th 2025

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

TARA-002 Intravesical Therapy Generates High CR Rate in BCG-Naive NMIBC With CIS

December 3rd 2025

Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.

Silevertinib Drives CNS Responses in First-Line NSCLC With Non-Classical EGFR Mutations

December 3rd 2025

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025

December 3rd 2025

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Updated Cosibelimab Label Reflects Long-Term Data in Advanced CSCC

December 2nd 2025

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Copanlisib/Ibrutinib Data Highlight Potential for PI3K Inhibition in R/R PCNSL

December 2nd 2025

BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.